{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T19:41:42Z","timestamp":1793130102796,"version":"4.5.0"},"reference-count":99,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seminarsinnephrology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nephrology"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.semnephrol.2021.03.010","type":"journal-article","created":{"date-parts":[[2021,6,14]],"date-time":"2021-06-14T16:10:23Z","timestamp":1623687023000},"page":"156-167","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Prolactin and Other Pituitary Disorders in Kidney Disease"],"prefix":"10.1016","volume":"41","author":[{"given":"Wenyu","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark E.","family":"Molitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semnephrol.2021.03.010_bib0001","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1056\/NEJM197703172961103","article-title":"Galactorrhea: a study of 235 cases, including 48 with pituitary tumors","volume":"296","author":"Kleinberg","year":"1977","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0002","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1152\/physrev.2000.80.4.1523","article-title":"Prolactin: structure, function, and regulation of secretion","volume":"80","author":"Freeman","year":"2000","journal-title":"Physiol Rev"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0003","first-page":"241","article-title":"Dissociation of dopamine from its receptor as a signal in the pleiotropic hypothalamic regulation of prolactin secretion","volume":"13","author":"Martinez de la Escalera","year":"1992","journal-title":"Endocr Rev"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0004","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.neuron.2010.01.013","article-title":"Excitatory neuromodulator reduces dopamine release, enhancing prolactin secretion","volume":"65","author":"van den Pol","year":"2010","journal-title":"Neuron"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0005","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.brainresbull.2009.08.026","article-title":"Estrogen inhibits tuberoinfundibular dopaminergic neurons but does not cause irreversible damage","volume":"80","author":"Morel","year":"2009","journal-title":"Brain Res Bull"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0006","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0006-8993(00)02763-3","article-title":"Ovarian steroids influence the activity of neuroendocrine dopaminergic neurons","volume":"879","author":"DeMaria","year":"2000","journal-title":"Brain Res"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0007","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000054363","article-title":"Ovarian steroids modulate responsiveness to dopamine and expression of G-proteins in lactotropes","volume":"68","author":"Livingstone","year":"1998","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0008","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ecl.2005.09.011","article-title":"Pituitary disorders during pregnancy","volume":"35","author":"Molitch","year":"2006","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0009","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3109\/07420528809078555","article-title":"The circadian rhythms of thyrotrophin and prolactin secretion","volume":"5","author":"Salvador","year":"1988","journal-title":"Chronobiol Int"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0010","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0272-6386(85)80181-5","article-title":"Hyperprolactinemia in patients with renal insufficiency and chronic renal failure requiring hemodialysis or chronic ambulatory peritoneal dialysis","volume":"6","author":"Hou","year":"1985","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0011","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1210\/jcem-68-1-186","article-title":"Effect of oral zinc administration on prolactin and thymulin circulating levels in patients with chronic renal failure","volume":"68","author":"Travaglini","year":"1989","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0012","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1210\/jcem-50-5-846","article-title":"Metabolic clearance and secretion rates of human prolactin in normal subjects and in patients with chronic renal failure","volume":"50","author":"Sievertsen","year":"1980","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0013","first-page":"29","article-title":"Prolactin and the pituitary-gonadal axis in male uraemic patients on regular dialysis","volume":"82","author":"Hagen","year":"1976","journal-title":"Acta Endocrinol"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0014","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1177\/1557988317703207","article-title":"Sexual function and testosterone level in men with conservatively treated chronic kidney disease","volume":"11","author":"Fugl-Meyer","year":"2017","journal-title":"Am J Mens Health"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0015","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/hdi.12489","article-title":"Hyperprolactinemia in end-stage renal disease and effects of frequent hemodialysis","volume":"21","author":"Lo","year":"2017","journal-title":"Hemodial Int"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0016","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1210\/jcem-45-4-658","article-title":"Abnormalities in the regulation of prolactin in patients with chronic renal failure","volume":"45","author":"Ramirez","year":"1977","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0017","first-page":"651","article-title":"Prolactin responses to vasoactive intestinal polypeptide and thyrotropin releasing hormone in chronic renal failure","volume":"125","author":"Arnaout","year":"1991","journal-title":"Acta Endocrinol"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0018","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1210\/jcem-49-6-815","article-title":"Dissociation of prolactin response to thyrotropin-releasing hormone and metoclopramide in chronic renal failure","volume":"49","author":"Leroith","year":"1979","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0019","first-page":"237","article-title":"Pituitary hormones in women with chronic renal failure: the effect of chronic intermittent haemo- and peritoneal dialysis","volume":"80","author":"Olgaard","year":"1975","journal-title":"Acta Endocrinol"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0020","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1159\/000064079","article-title":"Time course of serum prolactin and sex hormones following successful renal transplantation","volume":"92","author":"Saha","year":"2002","journal-title":"Nephron"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0021","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1159\/000484992","article-title":"Impact of kidney transplantation on reproductive hormone levels in males: a longitudinal study","volume":"138","author":"Eckersten","year":"2018","journal-title":"Nephron"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0022","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1046\/j.1365-2265.1999.00757.x","article-title":"Macroprolactinaemia: validation and application of the polyethylene glycol precipitation test and clinical characterization of the condition","volume":"51","author":"Olukoga","year":"1999","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0023","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/ncpendmet0447","article-title":"Technology insight: measuring prolactin in clinical samples","volume":"3","author":"Smith","year":"2007","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0024","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1365-2265.1985.tb03236.x","article-title":"Comparison between bioactivity and immunoreactivity of serum prolactin in uraemia","volume":"22","author":"Mooradian","year":"1985","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0025","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1210\/jcem-62-2-352","article-title":"Molecular heterogeneity of circulating prolactin in chronic uremic men and renal transplant recipients","volume":"62","author":"Rodriguez-Puyol","year":"1986","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0026","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/j.1365-2265.2005.02375.x","article-title":"Macroprolactin does not contribute to elevated levels of prolactin in patients on renal replacement therapy","volume":"63","author":"Yavuz","year":"2005","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0027","doi-asserted-by":"crossref","first-page":"33","DOI":"10.5414\/CN107061","article-title":"Serum prolactin and macroprolactin levels in diabetic nephropathy","volume":"78","author":"Sari","year":"2012","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0028","first-page":"1073","article-title":"Evaluation and management of galactorrhea","volume":"85","author":"Huang","year":"2012","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0029","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1056\/NEJMra035692","article-title":"Benign breast disorders","volume":"353","author":"Santen","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0030","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3949\/ccjm.69.5.425","article-title":"Benign breast disease: when to treat, when to reassure, when to refer","volume":"69","author":"Vaidyanathan","year":"2002","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0031","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1530\/EJE-15-0359","article-title":"Prevalence of subnormal testosterone concentrations in men with type 2 diabetes and chronic kidney disease","volume":"173","author":"Dhindsa","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0032","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1016\/j.transproceed.2014.07.017","article-title":"Sexual dysfunction in patients with chronic renal disease: does it improve with renal transplantation?","volume":"46","author":"Pertuz","year":"2014","journal-title":"Transplant Proc"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0033","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2215\/CJN.06840711","article-title":"Prolactin levels, endothelial dysfunction, and the risk of cardiovascular events andmortality in patients with CKD","volume":"7","author":"Carrero","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0034","first-page":"308","article-title":"Bromocriptine improves reduced libido and potency in men receiving maintenance hemodialysis","volume":"20","author":"Muir","year":"1983","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0035","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/j.1939-4640.1985.tb00825.x","article-title":"Testosterone levels after bromocriptine treatment in patients undergoing long-term hemodialysis","volume":"6","author":"Vircburger","year":"1985","journal-title":"J Androl"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0036","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1159\/000182087","article-title":"Hyperprolactinemia in chronic renal failure: impaired responsiveness to stimulation and suppression. Normalization after transplantation","volume":"28","author":"Peces","year":"1981","journal-title":"Nephron"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0037","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s11102-008-0106-6","article-title":"Drugs and prolactin","volume":"11","author":"Molitch","year":"2008","journal-title":"Pituitary"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0038","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1530\/EJE-09-0084","article-title":"Recovery of persistent hypogonadism by clomiphene in males with prolactinomas under dopamine agonist treatment","volume":"161","author":"Ribeiro","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0039","first-page":"543","article-title":"Diagnosis and management of galactorrhea","volume":"70","author":"Leung","year":"2004","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0040","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/BF03347016","article-title":"The midnight-to-morning urinary cortisol increment method is not reliable for the assessment of hypothalamic-pituitary-adrenal insufficiency in patients with end-stage kidney disease","volume":"26","author":"Oguz","year":"2003","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0041","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s11102-020-01066-8","article-title":"Outcomes of pituitary surgery for Cushing's disease: a systematic review and meta-analysis","volume":"23","author":"Stroud","year":"2020","journal-title":"Pituitary"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0042","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1001\/archinte.1982.00340210040010","article-title":"Evaluation of the hypothalamic hypophyseal adrenal axis in patients receiving long-term hemodialysis","volume":"142","author":"Ramirez","year":"1982","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0043","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1210\/jcem-50-1-46","article-title":"Pituitary-adrenocortical function in chronic renal failure: studies of episodic secretion of cortisol and dexamethasone suppressibility","volume":"50","author":"Wallace","year":"1980","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0044","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1210\/jcem-48-1-92","article-title":"Adrenocorticotropin-cortisol axis abnormalities in hemodialysis patients","volume":"48","author":"McDonald","year":"1979","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0045","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1530\/EC-12-0058","article-title":"Circadian rhythm of salivary cortisol, plasma cortisol, and plasma ACTH in end-stage renal disease","volume":"2","author":"Raff","year":"2013","journal-title":"Endocr Connect"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0046","doi-asserted-by":"crossref","first-page":"848","DOI":"10.3109\/07420528.2015.1048868","article-title":"An observational study on disturbed peripheral circadian rhythms in hemodialysis patients","volume":"32","author":"Russcher","year":"2015","journal-title":"Chronobiol Int"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0047","doi-asserted-by":"crossref","first-page":"R11","DOI":"10.1016\/0303-7207(94)90176-7","article-title":"Cloning and tissue distribution of the human 11 beta-hydroxysteroid dehydrogenase type 2 enzyme","volume":"105","author":"Albiston","year":"1994","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0048","doi-asserted-by":"crossref","first-page":"3622","DOI":"10.1210\/jc.2012-1411","article-title":"Role of 11betaHSD type 2 enzyme activity in essential hypertension and children with chronic kidney disease (CKD)","volume":"97","author":"Mongia","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0049","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1053\/meta.2001.24213","article-title":"Assessing systemic 11beta-hydroxysteroid dehydrogenase with serum cortisone\/cortisol ratios in healthy subjects and patients with diabetes mellitus and chronic renal failure","volume":"50","author":"Homma","year":"2001","journal-title":"Metabolism"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0050","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1210\/jcem-60-5-848","article-title":"Differences in metabolic properties among cortisol, prednisolone, and dexamethasone in liver and renal diseases: accelerated metabolism of dexamethasone in renal failure","volume":"60","author":"Kawai","year":"1985","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0051","doi-asserted-by":"crossref","first-page":"4027","DOI":"10.1210\/jc.2014-2476","article-title":"Central hypoadrenalism","volume":"99","author":"Crowley","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0052","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.2169\/internalmedicine.53.1104","article-title":"Clinical manifestation of hypercalcemia caused by adrenal insufficiency in hemodialysis patients: a case-series study","volume":"53","author":"Sakao","year":"2014","journal-title":"Intern Med"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0053","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/ajkd.1998.v32.pm9669424","article-title":"Adrenal function in patients with chronic renal failure","volume":"32","author":"Clodi","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0054","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1046\/j.1365-2265.2000.01057.x","article-title":"The low dose ACTH stimulation test is less sensitive than the overnight metyrapone test for the diagnosis of secondary hypoadrenalism","volume":"53","author":"Soule","year":"2000","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0055","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1016\/S0140-6736(13)61684-0","article-title":"Adrenal insufficiency","volume":"383","author":"Charmandari","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0056","doi-asserted-by":"crossref","first-page":"4193","DOI":"10.1210\/jc.2002-021897","article-title":"Diagnosis of adrenal insufficiency: evaluation of the corticotropin-releasing hormone test and basal serum cortisol in comparison to the insulin tolerance test in patients with hypothalamic-pituitary-adrenal disease","volume":"88","author":"Schmidt","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0057","first-page":"63","article-title":"The effects of corticotropin and growth hormone releasing hormones on their respective secretory axes in chronic hemodialysis patients before and after correction of anemia with recombinant human erythropoietin","volume":"78","author":"Ramirez","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0058","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1177\/089686089001000206","article-title":"Pituitary adrenal responsiveness to corticotropin-releasing hormone in chronic uremic patients","volume":"10","author":"Siamopoulos","year":"1990","journal-title":"Perit Dial Int"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0059","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S2213-8587(14)70142-1","article-title":"Diagnosis and management of adrenal insufficiency","volume":"3","author":"Bancos","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0060","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1210\/jc.2008-0125","article-title":"The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline","volume":"93","author":"Nieman","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0061","series-title":"Williams textbook of endocrinology","article-title":"The adrenal cortex","author":"Stewart","year":"2008"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0062","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/cen.13023","article-title":"Dynamics of salivary cortisol in chronic kidney disease patients at stages 1 through 4","volume":"85","author":"Cardoso","year":"2016","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0063","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1210\/jcem-63-3-741","article-title":"Dexamethasone suppression testing in chronic renal failure: pharmacokinetics of dexamethasone and demonstration of a normal hypothalamic-pituitary-adrenal axis","volume":"63","author":"Workman","year":"1986","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0064","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1210\/jcem-54-3-528","article-title":"Pituitary-adrenocortical function in chronic renal failure: blunted suppression and early escape of plasma cortisol levels after intravenous dexamethasone","volume":"54","author":"Rosman","year":"1982","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0065","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.ecl.2005.01.009","article-title":"Differential diagnosis and imaging in Cushing's syndrome","volume":"34","author":"Lindsay","year":"2005","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0066","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1373\/clinchem.2003.029934","article-title":"Diminished urinary free cortisol excretion in patients with moderate and severe renal impairment","volume":"50","author":"Chan","year":"2004","journal-title":"Clin Chem"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0067","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1530\/eje.0.1400148","article-title":"Undetectable urinary free cortisol concentrations in a case of Cushing's disease","volume":"140","author":"Issa","year":"1999","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0068","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.mce.2014.09.021","article-title":"Current approaches to the pharmacological management of Cushing's disease","volume":"408","author":"Molitch","year":"2015","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0069","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1210\/jc.2015-1818","article-title":"Treatment of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline","volume":"100","author":"Nieman","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0070","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1210\/jc.2014-2700","article-title":"Acromegaly: an endocrine society clinical practice guideline","volume":"99","author":"Katznelson","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0071","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1210\/er.2013-1071","article-title":"Growth hormone, insulin-like growth factor-1, and the kidney: pathophysiological and clinical implications","volume":"35","author":"Kamenicky","year":"2014","journal-title":"Endocr Rev"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0072","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/S0140-6736(68)92456-2","article-title":"Serum-growth hormone and glucose intolerance in renal failure","volume":"2","author":"Wright","year":"1968","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0073","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/BF03344187","article-title":"Acromegaly and end-stage renal disease: a diagnostic challenge","volume":"29","author":"Mussig","year":"2006","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0074","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/s11102-011-0325-0","article-title":"Somatotroph pituitary adenoma with acromegaly and autosomal dominant polycystic kidney disease: SSTR5 polymorphism and PKD1 mutation","volume":"15","author":"Syro","year":"2012","journal-title":"Pituitary"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0075","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/j.1365-2362.1992.tb01496.x","article-title":"Effect of a somatostatin analogue, octreotide, on renal haemodynamics and albuminuria in acromegalic patients","volume":"22","author":"Dullaart","year":"1992","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0076","first-page":"e104","article-title":"Pasireotide for a patient with acromegaly and chronic kidney disease on hemodialysis","volume":"5","author":"Adnan","year":"2019","journal-title":"AACE Clin Case Rep"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0077","doi-asserted-by":"crossref","DOI":"10.1152\/ajprenal.00604.2013","article-title":"The physiological and pathophysiological functions of renal and extrarenal vasopressin V2 receptors","volume":"306","author":"Juul","year":"2014","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0078","first-page":"207","article-title":"Effect of haemodialysis on plasma ADH levels, plasma renin activity and plasma aldosterone levels in patients with end-stage renal disease","volume":"110","author":"Iitake","year":"1985","journal-title":"Acta Endocrinol"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0079","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1042\/cs0830583","article-title":"Metabolic clearance rate of arginine vasopressin in severe chronic renal failure","volume":"83","author":"Argent","year":"1992","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0080","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1210\/jcem-45-4-714","article-title":"A study of plasma vasopressin in patients undergoing chronic hemodialysis","volume":"45","author":"Shimamoto","year":"1977","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0081","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1159\/000358203","article-title":"Dialysis hypotension: a role for inadequate increase in arginine vasopressin levels? A systematic literature review and meta-analysis","volume":"39","author":"Ettema","year":"2014","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0082","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1210\/jc.2014-2295","article-title":"Comparison between copeptin and vasopressin in a population from the community and in people with chronic kidney disease","volume":"99","author":"Roussel","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0083","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.clinbiochem.2015.07.031","article-title":"Plasma concentrations of novel cardiac biomarkers before and after hemodialysis session","volume":"48","author":"Mueller","year":"2015","journal-title":"Clin Biochem"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0084","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1172\/JCI118044","article-title":"Vasopressin resistance in chronic renal failure. Evidence for the role of decreased V2 receptor mRNA","volume":"96","author":"Teitelbaum","year":"1995","journal-title":"J Clin Invest"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0085","first-page":"158","article-title":"Effect of osmolar changes on plasma arginine vasopressin (PAVP) in dialysis patients","volume":"35","author":"Rosansky","year":"1991","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0086","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/j.1525-139X.2009.00615.x","article-title":"Endogenous and exogenous vasopressin during hemodialysis","volume":"22","author":"Thompson","year":"2009","journal-title":"Semin Dial"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0087","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/sj.ki.5001885","article-title":"Vasopressin administration facilitates fluid removal during hemodialysis","volume":"71","author":"van der Zee","year":"2007","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0088","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1056\/NEJM196905222802101","article-title":"Vasopressin-resistant hyposthenuria in advanced chronic renal disease","volume":"280","author":"Tannen","year":"1969","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0089","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1016\/j.transproceed.2013.02.141","article-title":"Newly developed central diabetes insipidus following kidney transplantation: a case report","volume":"45","author":"Kim","year":"2013","journal-title":"Transplant Proc"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0090","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s11102-010-0259-y","article-title":"Unmasking of undiagnosed pre-existing central diabetes insipidus after renal transplantation","volume":"15","author":"Kim","year":"2012","journal-title":"Pituitary"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0091","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1056\/NEJMcp066837","article-title":"Clinical practice. The syndrome of inappropriate antidiuresis","volume":"356","author":"Ellison","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0092","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1093\/ndt\/gfs038","article-title":"Significance of hypo- and hypernatremia in chronic kidney disease","volume":"27","author":"Kovesdy","year":"2012","journal-title":"Nephrol Dial Transplant."},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0093","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/nrneph.2013.22","article-title":"Vasopressin: a novel target for the prevention and retardation of kidney disease?","volume":"9","author":"Bankir","year":"2013","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0094","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/ki.2012.225","article-title":"Autosomal dominant polycystic kidney disease is associated with central and nephrogenic defects in osmoregulation","volume":"82","author":"Ho","year":"2012","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0095","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1053\/j.ajkd.2012.08.038","article-title":"Relationship of copeptin, a surrogate marker for arginine vasopressin, with change in total kidney volume and GFR decline in autosomal dominant polycystic kidney disease: results from the CRISP cohort","volume":"61","author":"Boertien","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0096","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1007\/s10157-015-1101-7","article-title":"Association of arginine vasopressin surrogate marker urinary copeptin with severity of autosomal dominant polycystic kidney disease (ADPKD)","volume":"19","author":"Nakajima","year":"2015","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0097","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/nrneph.2015.39","article-title":"Vasopressin and disruption of calcium signalling in polycystic kidney disease","volume":"11","author":"Chebib","year":"2015","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0098","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1111\/j.1523-1755.2005.00703.x","article-title":"Vasopressin antagonists in polycystic kidney disease","volume":"68","author":"Torres","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2021.03.010_bib0099","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N Engl J Med"}],"container-title":["Seminars in Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929521000413?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929521000413?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T23:39:41Z","timestamp":1759448381000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0270929521000413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":99,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S0270929521000413"],"URL":"https:\/\/doi.org\/10.1016\/j.semnephrol.2021.03.010","relation":{},"ISSN":["0270-9295"],"issn-type":[{"value":"0270-9295","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prolactin and Other Pituitary Disorders in Kidney Disease","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nephrology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semnephrol.2021.03.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}